Generic name: FERRIC CARBOXYMALTOSE 50mg in 1mL
Dosage form: injection, solution
Medically reviewed by Drugs.com. Last updated on Feb 1, 2020.
2.1 Recommended Dosage
Recommended dosage for patients weighing 50 kg (110 lb) or more: Give Injectafer in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.
Recommended dosage for patients weighing less than 50 kg (110 lb): Give Injectafer in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.
Each mL of Injectafer contains 50 mg of elemental iron.
2.2 Preparation and Administration
Administer Injectafer intravenously, either as an undiluted slow intravenous push or by infusion. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.
When added to an infusion bag containing 0.9% sodium chloride injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Injectafer solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.
Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Injectafer is intended for single-dose only.
When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. Avoid extravasation of Injectafer since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Injectafer administration at that site.
Discard unused portion.
2.3 Repeat Treatment Monitoring Safety Assessment
Injectafer treatment may be repeated if iron deficiency anemia reoccurs. Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment [see Warnings and Precautions (5.2)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Injectafer (ferric carboxymaltose)
- Side Effects
- During Pregnancy
- Drug Interactions
- Pricing & Coupons
- En Español
- 2 Reviews
- Drug class: iron products
- FDA Approval History